Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial.
Saved in:
| Title: | Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial. |
|---|---|
| Authors: | Hohlfeld JM; Fraunhofer Institute for Toxicology and Experimental Medicine and Hannover Medical School, Member of the German Center for Lung Research, Hannover, Germany., Badorrek P; Fraunhofer Institute for Toxicology and Experimental Medicine and Hannover Medical School, Member of the German Center for Lung Research, Hannover, Germany., Breuer O; EpiEndo Pharmaceuticals, Bjargargata 1, 102, Reykjavik, Iceland., Hanrott K; EpiEndo Pharmaceuticals, Bjargargata 1, 102, Reykjavik, Iceland., Kricker J; EpiEndo Pharmaceuticals, Bjargargata 1, 102, Reykjavik, Iceland., Parnham MJ; EpiEndo Pharmaceuticals, Bjargargata 1, 102, Reykjavik, Iceland., Norris V; EpiEndo Pharmaceuticals, Bjargargata 1, 102, Reykjavik, Iceland. Electronic address: ginny.norris@epiendo.com. |
| Source: | Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2025 Sep; Vol. 90, pp. 102365. Date of Electronic Publication: 2025 Jun 03. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Academic Press Country of Publication: England NLM ID: 9715279 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-9629 (Electronic) Linking ISSN: 10945539 NLM ISO Abbreviation: Pulm Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
